Tin tức & Cập nhật

Greater chemo use confers small survival benefit in elderly prostate cancer patients

09 May 2020

In the era of combination chemotherapy (CCE), clinical practice for treating elderly patients with metastatic prostate cancer (mPC) appears to be changing despite limited data, a recent study has shown.

Greater chemo use confers small survival benefit in elderly prostate cancer patients

09 May 2020

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

08 May 2020

Extragonadal steroids have significant contributions to the activation of the androgen receptor axis pathway at castration levels of testosterone in patients with recurrent nonmetastatic prostate cancer, suggests a study. In addition, these steroids promote the development of castration resistance following primary local treatment.

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

08 May 2020

Veliparib continues to show positive signals in ovarian cancer

08 May 2020 bởi

Subgroup analyses of the VELIA* trial showed that the concomitant administration of the poly(adenosine diphosphate-ribose) polymerase inhibitor veliparib with an induction chemotherapy (CT) regimen comprising carboplatin and paclitaxel (CP) generated antitumour activity and favourable safety in women with high-grade serous ovarian cancer.

Veliparib continues to show positive signals in ovarian cancer

08 May 2020

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

Elderly patients of pancreatic ductal adenocarcinoma suffer from worse health-related quality of life (HRQoL), particularly in terms of physical health status, a recent study has found.

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA PEMBROLIZUMAB TRONG UNG THƯ BIỂU MÔ TẾ BÀO GAN NGUYÊN PHÁT TIẾN TRIỂN SAU ĐIỀU TRỊ VỚI SORAFENIB

07 May 2020

Pembrolizumab là một kháng thể đơn dòng kháng PD-1, có hoạt tính kháng bướu, được chứng minh hiệu quả trong nhiều bệnh lý ung thư khác nhau như: u hắc tố, ung thư phổi không tế bào nhỏ, ung thư đầu cổ…với hồ sơ an toàn có thể quản lý được.(3) Vì vậy, vai trò của pembrolizumab cũng đã được đánh giá trên bệnh nhân UTBMTBG qua nghiên cứu KEYNOTE-224.

HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA PEMBROLIZUMAB TRONG UNG THƯ BIỂU MÔ TẾ BÀO GAN NGUYÊN PHÁT TIẾN TRIỂN SAU ĐIỀU TRỊ VỚI SORAFENIB

07 May 2020

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

07 May 2020 bởi

The use of durvalumab in combination with olaparib and paclitaxel significantly improves pathological complete response (pCR) rate vs paclitaxel alone in patients with high-risk HER2-negative stage II/III breast cancer, new results of the I-SPY 2 trial have shown.

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

07 May 2020

$Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM$

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

06 May 2020

Once-weekly treatment with carfilzomib at the higher 70-mg/m2 dose appears to improve survival in patients with relapsed and refractory multiple myeloma (RRMM) compared with the twice-weekly 27-mg/m2 dosing regimen, regardless of patient and disease characteristics, according to data from the phase III ARROW study.

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

06 May 2020

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

06 May 2020

Low preoperative prognostic nutritional index (PNI) has a significant impact on the completion of planned adjuvant chemotherapy (AC) following curative resection of stage II/III gastric cancer, a study has shown. Low PNI and incomplete AC confer an additive effect and lead to worse outcomes.

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

06 May 2020

Long-term PPI use does not increase GI cancer risk

06 May 2020 bởi

Use of proton-pump inhibitors (PPIs) for ≥2 years is not associated with a higher risk of gastrointestinal cancers, while the association of PPI use of ≥10 years with cancer risk remains unclear, reveals a study.

Long-term PPI use does not increase GI cancer risk

06 May 2020

Any polyps spell risk of colorectal cancer

05 May 2020 bởi

Patients with any subtypes of polyps had a greater risk of developing colorectal cancer (CRC) than the general population in a largely screening-naive Swedish cohort, indicating that CRC risk is not limited to just those with advanced histology, reveals a large registry-based study.

Any polyps spell risk of colorectal cancer

05 May 2020

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Greater chemo use confers small survival benefit in elderly prostate cancer patients

Greater chemo use confers small survival benefit in elderly prostate cancer patients

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

Extragonadal steroids influence androgen receptor activity, castration resistance in prostate cancer

Veliparib continues to show positive signals in ovarian cancer

Veliparib continues to show positive signals in ovarian cancer

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA PEMBROLIZUMAB TRONG UNG THƯ BIỂU MÔ TẾ BÀO GAN NGUYÊN PHÁT TIẾN TRIỂN SAU ĐIỀU TRỊ VỚI SORAFENIB

HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA PEMBROLIZUMAB TRONG UNG THƯ BIỂU MÔ TẾ BÀO GAN NGUYÊN PHÁT TIẾN TRIỂN SAU ĐIỀU TRỊ VỚI SORAFENIB

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

Once-weekly better than twice-weekly carfilzomib dosing for relapsed, refractory MM

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

Low PNI, incomplete adjuvant chemotherapy worsens survival after gastric cancer resection

Long-term PPI use does not increase GI cancer risk

Long-term PPI use does not increase GI cancer risk

Any polyps spell risk of colorectal cancer

Any polyps spell risk of colorectal cancer